Literature DB >> 10486203

Molecular cloning and characterization of the human glycogen synthase kinase-3beta promoter.

K F Lau1, C C Miller, B H Anderton, P C Shaw.   

Abstract

Glycogen synthase kinase 3beta (GSK-3beta) is a proline-directed kinase that forms part of the wingless signaling pathway. Recent studies have shown that GSK-3beta phosphorylates the microtubule-associated protein tau in vitro and in cell culture. Tau is the principal component of the paired helical filaments (PHFs) found in the brains of patients with Alzheimer disease, and PHF-tau is hyperphosphorylated. GSK-3beta is therefore one of the candidate kinases for phosphorylating tau in Alzheimer disease. GSK-3beta activity is negatively regulated by phosphorylation on serine 9 and positively regulated by phosphorylation on tyrosine 216. However, since overexpression of GSK-3beta by transfection leads to increased activity in the absence of any stimuli, GSK-3beta activity may also be regulated at the transcriptional level. Indeed, increased GSK-3beta protein levels are found in Alzheimer disease brains, and GSK-3beta is found associated with PHFs in Alzheimer disease. To understand how GSK-3beta activity may be regulated at the transcriptional level, we have isolated the human GSK-3beta promoter. The GSK-3beta promoter does not contain a conventional TATA box although several other transcription factor binding sites were identified. A putative transcription start site was mapped by 5' RACE. Transfection of various GSK-3beta promoter CAT reporter genes into both COS-7 cells and SHSY5Y neuronal cells revealed that the GSK-3beta promoter is more active in neuronal cells. Such transfection studies involving promoter deletion mutants revealed that a negative transcriptional response element may be present at position -1421 to -1363 and an activator sequence at position -427 to -384. CP2 binding sites were also present within the promoter. CP2 has recently been shown to interact with the Alzheimer disease amyloid precursor protein binding protein Fe65. The significance of these results with respect to Alzheimer disease pathogenesis are discussed. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10486203     DOI: 10.1006/geno.1999.5875

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  16 in total

1.  Late Simian virus 40 transcription factor is a target of the phosphoinositide 3-kinase/Akt pathway in anti-apoptotic Alzheimer's amyloid precursor protein signalling.

Authors:  Tarek Kashour; Teralee Burton; Alexander Dibrov; Francis M Amara
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

2.  Mutant K-Ras increases GSK-3β gene expression via an ETS-p300 transcriptional complex in pancreatic cancer.

Authors:  J-S Zhang; A Koenig; A Harrison; A V Ugolkov; M E Fernandez-Zapico; F J Couch; D D Billadeau
Journal:  Oncogene       Date:  2011-03-28       Impact factor: 9.867

Review 3.  Multitargeting by curcumin as revealed by molecular interaction studies.

Authors:  Subash C Gupta; Sahdeo Prasad; Ji Hye Kim; Sridevi Patchva; Lauren J Webb; Indira K Priyadarsini; Bharat B Aggarwal
Journal:  Nat Prod Rep       Date:  2011-10-06       Impact factor: 13.423

Review 4.  Lineage-specific and ubiquitous biological roles of the mammalian transcription factor LSF.

Authors:  Jelena Veljkovic; Ulla Hansen
Journal:  Gene       Date:  2004-12-08       Impact factor: 3.688

5.  Phosphorylation of amyloid precursor protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain and induces neurodegeneration.

Authors:  Keun-A Chang; Hye-Sun Kim; Tae-Young Ha; Ji-Won Ha; Ki Young Shin; Yun Ha Jeong; Jean-Pyo Lee; Cheol-Hyoung Park; Seonghan Kim; Tae-Kyoung Baik; Yoo-Hun Suh
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

6.  FE65 in Alzheimer's disease: neuronal distribution and association with neurofibrillary tangles.

Authors:  B Delatour; L Mercken; K H El Hachimi; M A Colle; L Pradier; C Duyckaerts
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

7.  Functional genetic variation in the Rev-Erbα pathway and lithium response in the treatment of bipolar disorder.

Authors:  M J McCarthy; C M Nievergelt; T Shekhtman; D F Kripke; D K Welsh; J R Kelsoe
Journal:  Genes Brain Behav       Date:  2011-09-02       Impact factor: 3.449

8.  A cAMP and CREB-mediated feed-forward mechanism regulates GSK3β in polycystic kidney disease.

Authors:  Vijayakumar R Kakade; Shixin Tao; Madhumitha Rajagopal; Xia Zhou; Xiaogang Li; Alan S L Yu; James P Calvet; Pankaj Pandey; Reena Rao
Journal:  J Mol Cell Biol       Date:  2016-05-04       Impact factor: 6.216

9.  Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease.

Authors:  Camila Teixeira Mendes; Fábio Borges Mury; Eloísa de Sá Moreira; Fernando Lopes Alberto; Orestes Vicente Forlenza; Emmanuel Dias-Neto; Wagner Farid Gattaz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-10-17       Impact factor: 5.270

10.  Effects of the G(-656)A variant on CREB1 promoter activity in a neuronal cell line: interactions with gonadal steroids and stress.

Authors:  G S Zubenko; H B Hughes
Journal:  Mol Psychiatry       Date:  2008-03-04       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.